Thursday, July 3, 2025 7/3/2025

Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia

Award Number: R01CA210637
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/06/2017
PERIOD OF PERFORMANCE END DATE: 02/28/2023

Group Awards By:

View Award Description

Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia - Recent evidence has provided an understanding of the molecular mechanisms and genetic changes underlying pancreatic ductal adenocarcinoma (PDAC) pathogenesis; however, limited information is available on progression in the disease. Studies in several genetically engineered mouse models for PDAC suggest that acinar cells, centroacinar cells, and/or postulated stem cells can be responsible for the development of PDAC. This is believed to occur via a process termed “acinar-to-ductal metaplasia” (ADM), during which a differentiated cell type (acinar) is reversibly replaced with another mature, differentiated cell type, a condition also visible during inflammation, thereby underlining the predisposition of chronic pancreatitis patients to PDAC. Pancreatic differentiation 2 (PD2), also known as polymerase associated factor-1 (Paf1), has been found to be overexpressed in PDAC and to exhibit oncogenic potential. Our previous studies have further defined the role of PD2/Paf1 in cell cycle regulation and in inducing chromatin structure remodeling in PDAC cells. We have also demonstrated that PD2/Paf1 plays a major role in the multi-lineage differentiation of mouse embryonic stem cells and maintains pancreatic cancer stem cells (PCSCs). Our preliminary efforts to investigate the expression of PD2/Paf1 in KrasG12D;Pdx1Cre mouse model of PDAC showed that it is differentially overexpressed in neoplastic pancreatic ducts during murine PDAC progression, as compared to its strictly acinar expression in normal pancreas. PD2/Paf1 was specifically expressed in `intermediate structures' expressing both acinar and ductal specific markers, representing `transitional cells' during pancreatic acinar to ductal metaplasia. Further, we found that PD2/Paf1 is overexpressed along with PCSCs markers in PDAC progression in mouse tissues and isolated CSCs. The multi-potent property of these CSCs allows them to differentiate into several cell types. Therefore, the overall goal of this study is to define the role of PD2/Paf1 in trans-differentiation of acinar cells to ductal cells during PDAC progression, through lineage- differentiation of pancreatic CSC population. Based on these observations our central hypothesis is that “PD2/Paf1 plays a significant role in the process of acinar-to-ductal metaplasia, thereby contributing to PDAC progression, and its overexpression contributes to the ductal lineage-differentiation of pancreatic CSCs.” To test this hypothesis, Aim 1 will focus on investigating the potential link of PD2/Paf1 in acinar-to-ductal metaplasia using cerulein-induced mouse model of PDAC progression. Aim 2 will elucidate the mechanism(s) of PD2/Paf1 in acinar-to-ductal metaplasia using acinar cells, organoid 3D-cultures, and PD2-/- animals. In Aim 3, we will understand the functional mechanism of PD2/Paf1 in ductal lineage-differentiation of pancreatic CSCs in PDAC progression. Taken together, understanding of novel roles of PD2/Paf1 in ADM progression through stem-like cell differentiation will lead to critical information for the long-term goal of developing novel, targeted therapy against PDAC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$6,494 )
2024	2021	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	987835 NEBRASKA MEDICAL CENTER	OMAHA	NE	68198	DOUGLAS	USA	Cancer Biology Research	000	5	12/5/2023	NON-COMPETING CONTINUATION	-$6,494
														Subtotal = -$6,494

Issue Date FY: 2021 ( Subtotal = $421,180 )
2021	2021	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	987835 NEBRASKA MEDICAL CENTER	OMAHA	NE	68198	DOUGLAS	USA	Cancer Biology Research	000	5	2/18/2021	NON-COMPETING CONTINUATION	$421,180
														Subtotal = $421,180

Issue Date FY: 2020 ( Subtotal = $421,180 )
2020	2020	UNIVERSITY OF NEBRASKA	987835 NEBRASKA MEDICAL CENTER	OMAHA	NE	68198	DOUGLAS	USA	Cancer Biology Research	000	4	2/24/2020	NON-COMPETING CONTINUATION	$421,180
														Subtotal = $421,180

Issue Date FY: 2019 ( Subtotal = $409,964 )
2019	2019	UNIVERSITY OF NEBRASKA	987835 NEBRASKA MEDICAL CENTER	OMAHA	NE	68198	DOUGLAS	USA	Cancer Biology Research	000	3	1/30/2019	NON-COMPETING CONTINUATION	$362,607
2019	2019	UNIVERSITY OF NEBRASKA	987835 NEBRASKA MEDICAL CENTER	OMAHA	NE	68198	DOUGLAS	USA	Cancer Biology Research	001	3	5/8/2019	SUPPLEMENT FOR EXPANSION	$47,357
														Subtotal = $409,964

Issue Date FY: 2018 ( Subtotal = $373,823 )
2018	2018	UNIVERSITY OF NEBRASKA	987835 NEBRASKA MEDICAL CENTER	OMAHA	NE	68198	DOUGLAS	USA	Cancer Biology Research	000	2	2/5/2018	NON-COMPETING CONTINUATION	$336,440
2018	2018	UNIVERSITY OF NEBRASKA	987835 NEBRASKA MEDICAL CENTER	OMAHA	NE	68198	DOUGLAS	USA	Cancer Biology Research	001	2	5/23/2018	NON-COMPETING CONTINUATION	$37,383
														Subtotal = $373,823

Issue Date FY: 2017 ( Subtotal = $373,823 )
2017	2017	UNIVERSITY OF NEBRASKA	987835 NEBRASKA MEDICAL CENTER	OMAHA	NE	68198	DOUGLAS	USA	Cancer Biology Research	000	1	3/6/2017	NEW	$373,823
														Subtotal = $373,823

Grand Total All Awards = $1,993,476

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia

Award Number: R01CA210637

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/06/2017

PERIOD OF PERFORMANCE END DATE: 02/28/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer